J. Ferlay, E. Steliarova-foucher, J. Lortet-tieulent, S. Rosso, J. Coebergh et al., Cancer incidence and mortality patterns in Europe: estimates for, vol.40

, Eur J Cancer Oxf Engl, vol.49, issue.6, pp.1374-403, 1990.

W. D. Travis, E. Brambilla, A. G. Nicholson, Y. Yatabe, J. Austin et al., The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification, J Thorac Oncol. 1 sept, vol.10, issue.9, pp.1243-60, 2015.

F. C. Detterbeck, D. J. Boffa, A. W. Kim, and L. T. Tanoue, The Eighth Edition Lung Cancer Stage Classification, Chest. janv, vol.151, issue.1, pp.193-203, 2017.

S. J. Antonia, A. Villegas, D. Daniel, D. Vicente, S. Murakami et al., Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer, N Engl J Med, vol.16, issue.20, pp.1919-1948, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01753457

M. Reck, D. Rodríguez-abreu, A. G. Robinson, R. Hui, T. Cs?szi et al., Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

, N Engl J Med, vol.10, pp.1823-1856, 2016.

P. Goldstraw, K. Chansky, J. Crowley, R. Rami-porta, H. Asamura et al., The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer, J Thorac Oncol. janv, vol.11, issue.1, pp.39-51, 2016.

J. Brahmer, K. L. Reckamp, P. Baas, L. Crinò, W. Eberhardt et al., Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med. 9 juill, vol.373, issue.2, pp.123-158, 2015.

H. Borghaei, L. Paz-ares, L. Horn, D. R. Spigel, M. Steins et al., Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, issue.17, pp.1627-1666, 2015.

N. Daaboul, G. Nicholas, and S. A. Laurie, Algorithm for the treatment of advanced or metastatic squamous non-small-cell lung cancer: an evidence-based overview, Curr Oncol. 14 juin, vol.25, issue.0, pp.77-85, 2018.

D. M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer. 22 mars, vol.12, issue.4, pp.252-64, 2012.

R. D. Harvey, Immunologic and clinical effects of targeting PD-1 in lung cancer, Clin Pharmacol Ther. août, vol.96, issue.2, pp.214-237, 2014.

S. Bockel, A. D. Deutsch, É. Mornex, and F. ,

, Cancer Radiother J Soc Francaise Radiother Oncol. mai, vol.21, issue.3, pp.244-55, 2017.

S. Demaria, E. B. Golden, and S. C. Formenti, Role of Local Radiation Therapy in Cancer Immunotherapy, JAMA Oncol. déc, vol.1, issue.9, pp.1325-1357, 2015.

S. J. Dovedi, A. L. Adlard, G. Lipowska-bhalla, C. Mckenna, S. Jones et al., Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade, Cancer Res, vol.74, pp.5458-68, 2014.

M. Z. Dewan, A. E. Galloway, N. Kawashima, J. K. Dewyngaert, J. S. Babb et al., Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody, Clin Cancer Res Off J Am Assoc Cancer Res. 1 sept, vol.15, issue.17, pp.5379-88, 2009.

S. S. Park, H. Dong, X. Liu, S. M. Harrington, C. J. Krco et al., PD-1 Restrains Radiotherapy-Induced Abscopal Effect, Cancer Immunol Res. juin, vol.3, issue.6, pp.610-619, 2015.

K. Reynders, T. Illidge, S. Siva, J. Y. Chang, D. Ruysscher et al., The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant, Cancer Treat Rev. juin, vol.41, issue.6, pp.503-513, 2015.

S. Du, L. Zhou, G. S. Alexander, K. Park, L. Yang et al., PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes, J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. avr, vol.13, issue.4, pp.510-530, 2018.

C. J. Myers and B. Lu, Decreased Survival After Combining Thoracic Irradiation and an Anti-PD-1 Antibody Correlated With Increased T-cell Infiltration Into Cardiac and Lung Tissues, Int J Radiat Oncol ? Biol ? Phys. 1 déc, vol.99, issue.5, pp.1129-1165, 2017.

M. A. Postow, M. K. Callahan, C. A. Barker, Y. Yamada, J. Yuan et al., Immunologic correlates of the abscopal effect in a patient with melanoma, N Engl J Med. 8 mars, vol.366, issue.10, pp.925-956, 2012.

N. Yamamoto, H. Nokihara, Y. Yamada, T. Shibata, Y. Tamura et al., Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors, Invest New Drugs, vol.35, issue.2, pp.207-223, 2017.

B. Lueza, Estimation du bénéfice de survie à partir de méta-analyse sur données individuelles et évaluation économique, 2016.

L. Horn, D. R. Spigel, E. E. Vokes, E. Holgado, N. Ready et al., Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057), J Clin Oncol Off J Am Soc Clin Oncol, 2017.

A. Aboudaram, A. Modesto, L. Chaltiel, C. Gomez-roca, S. Boulinguez et al., Concurrent radiotherapy for patients with metastatic melanoma and receiving antiprogrammed-death 1 therapy: a safe and effective combination, Melanoma Res, vol.27, issue.5, pp.485-91, 2017.

E. Liniker, A. M. Menzies, B. Y. Kong, A. Cooper, S. Ramanujam et al., Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma, Oncoimmunology, vol.5, issue.9, p.1214788, 2016.

K. A. Ahmed, D. G. Stallworth, Y. Kim, P. Johnstone, .. S. Harrison et al., Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy, Ann Oncol Off J Eur Soc Med Oncol. mars, vol.27, issue.3, pp.434-475, 2016.

A. Bang, T. J. Wilhite, L. Pike, D. N. Cagney, A. A. Aizer et al., Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy, Int J Radiat Oncol ? Biol ? Phys. 1 juin, vol.98, issue.2, pp.344-51, 2017.

W. L. Hwang, A. Niemierko, K. L. Hwang, H. Hubbeling, E. Schapira et al., Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy, JAMA Oncol, 2017.

H. G. Hubbeling, E. F. Schapira, N. K. Horick, K. Goodwin, J. J. Lin et al., Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer, J Thorac Oncol, vol.5, issue.2018

D. Sur,

M. Sznol, P. F. Ferrucci, D. Hogg, M. B. Atkins, P. Wolter et al., Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma, J Clin Oncol Off J Am Soc Clin Oncol. 1 déc, vol.35, issue.34, pp.3815-3837, 2017.

A. Lisberg, D. A. Tucker, J. W. Goldman, B. Wolf, J. Carroll et al., Treatment Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center, Cancer Immunol Res. 30 janv, 2018.

J. S. Weber, F. S. Hodi, J. D. Wolchok, S. L. Topalian, D. Schadendorf et al., Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma, J Clin Oncol Off J Am Soc Clin Oncol. mars, vol.35, issue.7, pp.785-92, 2017.

N. Shaverdian, A. E. Lisberg, K. Bornazyan, D. Veruttipong, J. W. Goldman et al., Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial, Lancet Oncol. juill, vol.18, issue.7, pp.895-903, 2017.

Y. Kataoka, N. Ebi, D. Fujimoto, S. Hara, K. Hirano et al., Prior radiotherapy does not predict nivolumab response in non-small cell lung cancer: a retrospective cohort study, Ann Oncol Off J Eur Soc Med Oncol. 20 mars, 2017.

R. C. Walshaw, J. Honeychurch, and T. M. Illidge, Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy?, Br J Radiol

R. Qin, A. Olson, B. Singh, S. Thomas, S. Wolf et al., Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab, Int J Radiat Oncol Biol Phys, vol.01, issue.1, pp.72-79, 2016.

A. P. Kiess, J. D. Wolchok, C. A. Barker, M. A. Postow, V. Tabar et al., Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment, Int J Radiat Oncol Biol Phys. 1 juin, vol.92, issue.2, pp.368-75, 2015.